Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $10.75

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been given a consensus recommendation of “Buy” by the eight research firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.75.

Several research firms recently weighed in on RZLT. Guggenheim began coverage on shares of Rezolute in a report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Craig Hallum began coverage on shares of Rezolute in a report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. BTIG Research boosted their price target on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Rezolute in a report on Monday, September 9th. Finally, Maxim Group boosted their price target on shares of Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, August 6th.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $5.25 on Thursday. The stock has a market capitalization of $210.71 million, a P/E ratio of -4.61 and a beta of 1.18. The company has a 50-day moving average price of $4.55 and a 200-day moving average price of $3.62. Rezolute has a 1 year low of $0.72 and a 1 year high of $6.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute in the second quarter valued at approximately $45,000. Virtu Financial LLC bought a new stake in shares of Rezolute in the first quarter valued at approximately $37,000. XTX Topco Ltd raised its position in shares of Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after purchasing an additional 22,660 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after acquiring an additional 42,597 shares during the period. Finally, Rosalind Advisors Inc. increased its holdings in Rezolute by 25.0% during the 2nd quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock worth $1,075,000 after acquiring an additional 50,000 shares during the period. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.